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Abstract
After preliminary review of relevant research articles, the thesis was able to gain a
deeper understanding of neurotechnological interventions (e.g. deep brain stimulation, and
other neurostimulators), specifically in regards to their use in treatment of motor conditions
(e.g. Parkinson’s, Epilepsy, etc.) and for some psychological disorders (e.g. depression, other
mood disorders, etc.). A scoping review was conducted on a specific class of treatments used
for particular conditions: invasive neurotechnological treatments for mood disorders. The
reasoning behind this specified approach was due to the lack standardized policies and
regulations in place for invasive neurotechnological interventions used for treatment of mood
disorders – in contrast to more policies and regulations for non-invasive interventions.
Therefore, the scoping review will attempt to cover research available based on other certain
attributes, such as: current regulations (e.g. FDA guidelines and CMS rules), economic
considerations, and any legal or ethical implications. Last, from such review, the thesis will
attempt to propose a recommended public health response to these treatments. It is hoped
that adoption of public health safeguards can ensure ethical and effective application of
invasive neurotechnological treatments for mood disorders.
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Introduction
Background
There is a growing use of neurostimulators and other neurotechnological interventions
as treatment for severe neurological ailments, typically as a last resort option for severe motor
or mood disorders, such as Parkinson’s disease or treatment-resistant depressive
disorder(Edwards C, 2017). Neurostimulators can be defined as “active implantable devices
that provide therapeutic intervention, sensory feedback or improved motor control via electric
stimulation of neural or neuro-muscular tissue in response to trauma or disease.”(Shephard,
R.L, 2018). For the purposes of the thesis, neurostimulators will be used interchangeably with
1) neurotechnological interventions, 2) neuromodulation techniques, and 3) neurostimulation
treatments or devices. Mood disorders will be used as a synonymous term for ‘psychiatric
disorders.’ Mood disorders can encompass, but not be limited to 1) Treatment-Resistant
Depression (TRD), 2) General Anxiety Disorder (GAD), and 3) Obsessive Compulsive Disorder
(OCD). Addiction disorders and others substance-related disorders may also be included when
necessary.
Common examples of invasive treatments used in treatment for mood disorders are
Deep Brain Stimulation (DBS) and Vagal Nerve Stimulation (VNS). (Wong, 2018). Other invasive
neurostimulation techniques are “motor cortex stimulation (MCS), responsive neurostimulation
(RNS), and spinal cord stimulation (SCS)” – but only have therapeutic use with movement
disorders, not mood disorders(Edwards C, 2017). Since most neurostimulators can be medical
devices, they are also classified by federal regulatory bodies like the Food and Drug
Administration (FDA)(Rome, 2014). The FDA classifies medical devices based on their
5

respective risk level, with devices with lower risk levels belonging to Class I and II, and thus have
“simple requirements for getting to the market” versus devices tiered into Class III (Shepard R,
2018). Implantable devices are considered to be implantable neurostimulators and are an
example of Class III devices. Thus, they will typically have longer testing requirements due to a
more stringent regulatory pathway which imposes additional testing (O’Neill T, 2019).
In contrast, non-invasive neuromodulation devices are not surgically implanted into the
patient (like they are in invasive treatments); thus, they are not ‘implantable’ medical devices
(Wong, 2018). Rather, non-invasive neurostimulation is the “process or technology that applies
electrical currents, in varying parameters, by.... inhibition of specific neuronal groups,
pathways, or networks.” (Edwards C, 2017). Examples include repetitive transcranial magnetic
stimulation (rTMS), which arguably is the most recommended neurostimulator for treatmentresistant depression (McClintock S, 2018).
Increased scientific research and innovation in the neurological fields have introduced
more emerging, novel treatments. As a result, there has been increased pressure on the FDA to
modernize its rules for an expedited approval process (Berglund J, 2014). Despite most
treatments’ regulation under the FDA as Class III medical devices, there is still a public health
risk due to the relatively lack of standardization among different treatment types (Krause J,
2018). For instance, some of the dangers posed from lack of standardized policies include
potentially unenforced public safety safeguards which are intended to protect and promote
public health(Krause J, 2014).
A preliminary search of past literature reviews and relevant research has been
conducted by the researcher. Based on such review, findings show a lack of standardized
6

policies on the regulation of novel and emerging uses of invasive neurotechnological
interventions for treatment of mood disorders.
In contrast, there is a more regulatory guidance, as well as FDA approval, for use of
noninvasive treatments for mood-related disorders (Shephard R, 2018)(Marjenin T, 2019).
Therefore, it is hypothesized that there is arguably little research on utilization, evidence, and
other applied areas with invasive neurotechnological treatments. It is also predicted that there
is lack of standardized policies and regulations in place, and by extension, no public health
safeguards to ensure ethical and effective application of neurotechnological treatments for
treating mood disorders.
The abovementioned points to a notable gap in the body of research for
neurostimulators, which this scoping review seeks to address. Additional research on the
treatment capabilities of invasive neurostimulators, as well as the risks posed by emerging
implantable devices, is of value to the scientific community. New research insights on emerging
invasive neurostimulators can also help guide better-informed policies, which can benefit the
public as well.
Furthermore, the thesis serves to highlight potentially beneficial treatment options for
serious psychological conditions. Taking depression as one example, it is estimated to have a
“lifetime prevalence of 15 to 20% in the United States [and be] the leading cause of years lost
to disability worldwide, and is 1 of the top 3 contributors to global burden of disease.”
(Filkowski M, 2017). Given the magnitude of mental health conditions, it is imperative to
consider the benefits and risks associated with invasive neurostimulators. While noninvasive
neurostimulators are approved for treatment in treatment-resistance depression, there is less
7

opportunities for invasive techniques to be available at treatment options (McGirr, 2018).
Reasons for this delta may simply be due to lower amounts of FDA-approved options for
invasive treatments and devices. The following is supported by a recent report provided by the
FDA’s Office of Neurological and Physical Medicine Devices (OHTS) as well as by the ‘larger
literature’ that was reviewed during the scoping review process (Marjenin, T, 2019).
Overall, a scoping review can be helpful to learn more about invasive neurostimulators’
capabilities with treating intractable mood disorders. Although still limited in their medical
application, further research and evaluation on such practices will be important to conduct. It
is the researcher’s objective that such scoping review can help evaluate and assess currently
available literature on invasive neurotechnological interventions for mood disorders.
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Methods
A scoping review will be conducted on select national databases, such as PubMed and
Cochrane Database Syst Review. There also may be additional inclusion of other research
articles outside of the scoping review which are determined to be relevant enough for
consideration. The initial scoping review will be performed with reference to the PRISMA-ScR checklist (Tricco, 2018). A scoping review was determined as best equipped to explore research
on the potential treatment capabilities offered by invasive neurostimulators, specifically for
mood disorders. Therefore, data on invasive neurotechnological interventions will be reviewed
based on their categorical research area, including but not limited to: type of invasive
treatment technique (e.g. DBS or VNS), specific mood disorders, study type, and applicable
policies or regulations. Based on the research findings, the thesis will suggest research
implications for potential future studies seeking to understand any present research gaps with
regards to invasive neurostimulators. In sum, the research question driving the scoping
strategy is: What are the regulations or policies for the different types of mood disorders which
invasive neurostimulation techniques can treat?

Search Strategy
A comprehensive search strategy is detailed in the Appendix, with a summarization
detailed under Table !. Searches were mostly conducted in Jan 24, 2020, and later to recheck in
April 2020, in PubMed and Cochrane Database System Review. Examples of search terms
included were “Deep Brain Stimulation” or “DBS” or “Vagus Nerve Stimulation” or “VNS” or
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“invasive neurostimulation” or “invasive brain stimulation” or “noninvasive brain stimulation”
AND in combination of “mood disorders” or “major depressive disorder” or “MDD.”
The above query was also repeated for other purposes outside the scoping review,
mainly to attain additional background information. This will be done by adding other terms
such as “recommendations” or “FDA” or “regulations” or “policies” or “economic evaluation” or
“ethical.” Synonymous terms and other associated terms were also employed in these
searches. Please reference the Appendix, Table I, and Figure ! for additional information on the
thesis’ search strategy, and other associated scoping review protocol, such as data extraction
information.

Inclusion Criteria
Relevant studies which discussed invasive neurostimulation treatments for mood
disorders, such as treatment-resistant depression (TRD) or obsessive-compulsion disorder
(OCD), were included in the scoping review. Some substance related disorders, such as
anorexia nervosa (AN) or cocaine dependence were also included in the scoping review.
However, studies which did not specify a particular type of substance abuse or drug addiction
was not included. Studies which discussed non-invasive treatments were not included.
Inclusion criteria for studies was set by their research design, with most including studies being
one of the following: randomized controlled trials (RCTs), evaluation studies, literature reviews,
study protocols, and government guidelines. Last, studies before the year 2017 were not
included in the scoping review due to time and budget constraints. More supplemental
information can be referenced in the Appendix.
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Table I: Summary of Data Extraction Process
Identification:

389 Entries

Excluded:

284

Additional Excluded (via Filtering):
Studies Included:
*added from individual hand search:
Total Studies Included

99
6
3
9

**please see Figure 1 and Appendix for more related information

Table II – Results of Scoping Review

Aaronson Casmari
(2018)
(2018)
Treatment
Type?

DBS
VNS

X

X

X

X

X

X

X (with
VNS)

X (with
both)

TreatmentResistant
Depression X (with both) X (with VNS)
For Which
Conditions?

OCD

Edwards Filkowski McGirr McIntyre( Milev Park
Rachid
(2016) (2018) (2018)
(2018)
(2019)
(2018) 2017 )

X (with DBS)

X

X (with both)

X

X

Type of Study

Review

Review

Review

Review

X

Medical
Guidelines

8 (88.89%)
5 (62.5%)
DBS: 5(62.5%);
VNS: 7(77.78 )*

X (with
X (with both) both)

Anorexia
Nervosa

Systemati
c metareview

X

X

X (with
DBS)

Addictions

X

No. (%) out of a
total of 9
Studies

X (with
DBS)

DBS: 3(33.33%)**
VNS: 0(0% )

X (with
DBS)

DBS: 1(62.5%)
VNS: 0(0%)

Medical
Guidelin
Study
Protocol
es

X (DBS; for
DBS: 1(11.11%);
Cocaine
VNS: 0(0% )
Dependence)
Review
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Table III - Important Information on Invasive Neurostimulators
Type of Neuromodulation
Technique
Deep Brain Stimulation

Type of Mood Disorder

Regulatory Status

Obsessive-compulsive disorder
(OCD)
Anorexia Nervosa

Indication only; Class IIII (has HIE
exemption since 2009)
Limited off-label use; clinical
evidence shows potential
therapeutic use
Limited off-label use; clinical
evidence shows potential
therapeutic use
Mixed research findings; ongoing
clinical trial

Drug Additions: Cocaine
Dependence, Opioid Addiction
Treatment-Resistant
Depression

Vagal Nerve Stimulation

Treatment-Resistant
Depression

Indication only; Class III

*information from Marjenin, T. et al.; Lee, Darrin., et al., etc.
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Included

Eligibility

Screening

Identification

Figure 1 – Charting Data Extraction Process: A Flow Chart

Records identified through
PubMed database searching
(n = 389 )

Records identified through
Cochrane database
searching
(n =3 )
Records after duplicates
removed (n =3 )

Total Records
screened
(n = 392)
Records excluded (n = 287 )
(Unrelated topic, not
English language, out of date range,
country of study outside of North
America)
Records eligible
for more screening
(n = 105 )

Additional Records
from Individual
Hand Searches (n =
3)

Additional records excluded (n
=100)
(bioengineering focus, not
related to subject, or out of
new date range [before 2017])

Total # of Studies
in scoping review
(n = 9 )
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Analysis
The scoping review analyzed 9 studies, as detailed in Table 2. Many dozens of other
studies were excluded for variety of reasons, as described in Table I and Figure I. Studies were
excluded mostly for three main reasons: 1) published language was not English language or the
journal was not in North America, 2) subject area of the research was unrelated to the thesis’s
objective (e.g. being too focused on the biomedical engineering aspect of devices) and 3)
focused on the wrong research areas of the scoping review (e.g. centered around “noninvasive” treatments or movement disorders). Supplemental exclusion criteria were set, which
is listed in the Appendix.
7 out of 9 studies in the scoping review (78% of total studies) were literature reviews
(from PubMed) that looked at the therapeutic uses of invasive neurostimulators for mood
disorders. The remaining 2 studies (22% of total studies) were government issued guidelines
concerning safety recommendations. One study was a guideline issued from the federal level in
Canada, while the other was at the U.S. state-level (McIntrye, 2018)(Milev, 2016). Looking
abroad to Canada, clinical guidelines issued for neurostimulation treatments used for the
“management of adults with major depressive disorder”, encompassed 6 types of
‘neurostimulation modalities’ – 4 of the 6 being noninvasive treatments (Milev, RV, 2016).
Intriguingly this pattern is the same in the U.S., with the about 4 of 6 of FDA-approved
neurostimulators being non-invasive treatments (Marjenin, T, 2019).
Regarding the uses of invasive neurostimulation treatments, the scoping review found
invasive neuromodulation treatments to be discussed in 9 of the 9 articles, as having
therapeutic use for at least one mood disorder. However, the other 2 out of 9 focused on
14

addiction related disorders. Overall, there was more emphasis on invasive treatments for
certain mood disorders, a recurrent characteristic of those studies which will be discussed in
greater detail in the Discussion and Conclusion section.
On another note, FDA approval of an Early Feasibility Studies (EFF) investigational device
exemption (IDE) was another indicator which was considered, but ultimately excluded. Per one
study, devices for neurological purposes composed of most EFF IDEs (Holmes, D.R; 2017)
However, given the limited data from a small sample size of EFF IDEs – which were only
available after 2016 (post-passage of the 21st Century Cures Act) – there is not much external
validity and so was excluded from the scoping review.
Thus, the majority of reviewed studies were 1) literature reviews on uses of invasive
neurostimulators, and 2) specifically for the treatment of mood disorders. The scoping review
also highlight noticeable patterns, as detailed in the Appendix and in Table 2. Overall, most
studies in the scoping review detailed invasive neurostimulators therapeutic uses in aiding
patients with treatment-resistant depression. Depression had the overall highest frequency in
being mentioned as a potentially treatable condition by the two main invasive techniques we
covered, VNS and DBS. However, Deep Brain Stimulation was more commonly discussed as an
intervention option, versus that of VNS. DBS was most covered for its treatment capabilities
with depression (5 out of 9 studies mentioning it), then next with ODC (per 3 out of 9 studies).
Similarly, vagal nerve stimulation was also mostly commonly cited as an intervention for
depression – and overall was the treatment type most mentioned for its therapeutic use with
treatment-resistant depression.
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Discussion
As discussed, it was noted that non-invasive treatments have historically (and
consistently) been used more for treatment-resistant depression by physicians. This is
especially true for repetitive transcranial magnetic stimulation (rTMS) in its treatment for
depressive disorders(McIntryre, 2018). Meanwhile, invasive treatments have been cited less as
treatments for major depression disorder, or in any other severe cases of mood disorders. In
fact, invasive neurostimulations are only approved for 2 indications, with DBS devices having a
rare HDE exception pertaining OCD and VNS having an indicated use for treatment-resistant
depression (Marjenin, T, 2019). Thus, there is a gap between noninvasive and invasive
neurostimulators, regarding its use in treating depression and other mood disorders.
The scoping review explored invasive neurostimulation techniques in hopes of adding
value to the abovementioned research area. Overall, analysis of the conducted scoping review
has thus far shown little information regarding invasive neurostimulation interventions as
treatment option for mood disorders. For instance, as detailed in Table II, the majority of both
VNS and DBS studies mention their therapeutic use with treatment-resistant depression.
However, this is not congruent with our findings for other severe psychological disorders, such
as Bipolar Affective Disease, General Anxiety Disorder, and Schizophrenia – which were not
substantially discussed in the articles included in the scoping review. Reasons for these findings
can be attributed to an array of factors, as discussed in the next section.
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Conclusion
Summary of findings
The scoping review did not find an abundance in information on invasive
neurostimulators’ therapeutic use with treating most cited psychiatric disorders (e.g. Bipolar
Disease, Attention Deficit-Hyperactive-Disorder, Bipolar, etc.) as we detailed in our results
(Table 2 for results). Treatment-resistant depression was the main exception to this rule, as
well as OCD to a limited degree - with most of the included studies covering DBS’ promising ongoing research with potentially treating TRD and OCD. It is also important to note that VNS is
the only invasive neuromodulation technique which is currently FDA-approved for indicated use
of TRD (Aaronson, 2018). Hence, most of the reviewed studies on VNS were based off a larger
amount of publicly available data, as VNS devices have been in the ‘marketplace’ longer than
DBS for depression (Mertens, 2018).
The current body of research points to the promising returns which VNS and DBS can
bring as a last-resort treatment option for intractable mood disorders. There is no doubt about
the transformational health improvements which both invasive neurostimulator treatments can
yield; however, there should be caution with attempts to prematurely challenge existing
regulatory barriers which serve the public health (Loftus C, 2018).
Furthermore, it is argued that the FDA’s authority to issue a Class III classification with
invasive neuropsychiatric devices is not sufficient enough, given the lack of federal guidelines
on invasive neurostimulators therapeutic use in psychiatric disorders (Krause, ). One proposed
solution is to study the case of two noninvasive neurostimulators’ therapeutic use with mood
disorders, which interestingly were able to change their regulatory pathway track from a PMA
17

pathway to a less stringent 501k pathway(Marjenin, 2019). However, the contextual
information is uncertain and remains speculative. Even more, advocating for a less stringent
approval process is not feasible for invasive neurostimulation devices, which are perceived to
be riskier due to their ‘implantable’ nature (Filkowski, 2017).

Limitations
The scoping review presents limitations in the amount of research it was able to cover,
given the relatively lack of FDA-approved invasive neuromodulation devices for mood and
anxiety disorder. The following limitation also guided our scoping review protocol with its
search criteria for included studies – which had to be based off clinical trials or off-label use
collected from 2017-2019. There is also a lack of publicly available data on the utilization
trends of invasive neurostimulators, as well as little research focused on either the economic or
ethical considerations of their growing research and medical application. While the scoping
review identified these limitations, it can also be perceived as future opportunities to guide
new and exciting research.

Concluding Remarks and Final Recommendation
The scoping review provides insights on potential roadblocks for further advancing the
adoption of new neurostimulation treatments. For instance, there is not much standardized
guidelines from regulatory bodies on both approved indications and off-label uses of invasive
neurostimulators for mood and anxiety disorders(Stahl, 2018 ). In addition, not much economic
evaluation or cost effect studies were able to be identified in the scoping review, and if they
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were, they were exclusively for non-invasive neurostimulation treatments (Niyazoa,
2018)(Voight, 201)(Mendlowitz, 2019).
Hence, future studies can contribute by attempting to conduct an economic evaluation
or a cost-effective analysis of treatment types for mood disorders. Understanding the
economic factors can be helpful not only to researchers, but also to all stakeholders: including
physicians, patients (consumers), and device manufacturers (Rome, 2014). Encouraging further
adoption of standardized best practices from more established medical practices can be a
valuable best practice to consider as well. This is stressed since non-invasive treatments
generally more clinical guidelines and safety recommendations for mood disorders than
invasive treatments, which is also another research opportunity for future follow up studies
(McClintock, 2018)(Perera, T, 2016).
Another case study worth considering for best practices is the relatively successful
adoption of cardiac pacemakers in patient care; thus, improving patient’s health and also
setting the framework for a new commercially successful market. On a similar note, ensuring
all stakeholders involvement in the regulatory approval process, including patients, is
paramount to the adoption of novel new neurotechnological intervention(Bergland, 2014).
In sum, the scoping review was able to identify the above areas where there is arguably
a need for more research. A final area also recommended for further research are other
therapeutic applications of neurostimulators, such as in substance related disorders. As
evidenced in the scoping review, there is growing clinical evidence of potentially life-saving
benefits which deep brain stimulation can have with treating patients afflicted with cocaine
dependence and other drug addictions. One therapeutic use for DBS can be with helping
19

individuals who are combating with Opioid Addiction. Further research and funds should invest
in our efforts to combat this public health crisis – which can potentially be lifesaving for many
thousands in the United States (Bernstein L, 2019).
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Appendix A - Supplemental Information for Scope Review
PubMed Search – Search 1:
Initial
Query:

("substance-related disorders"[MeSH Terms] OR "mood
disorders"[MeSH Terms] AND "neurostimulation"[tw]) OR
"invasive brain stimulation"[mh])

Additional AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR
systematic[sb] OR Practice Guideline[ptyp] OR
Filters to
Guideline[ptyp] OR Evaluation Study[ptyp] OR Randomized
include:

# of Included Studies
60 studies

17 studies

Controlled Trial[ptyp] ) AND "last 5 years"[PDat] AND
English[lang] AND ( systematic[sb] OR Review[ptyp] OR
Guideline[ptyp] OR Meta-Analysis[ptyp] OR Practice
Guideline[ptyp] OR Evaluation Study[ptyp] ) AND (
"2017/01/01"[PDat] : "2019/12/31"[PDat] ) AND
English[lang]

Modify
Change “AND last 5 years"[PDat with “AND (
"2017/01/01"[PDat] : "2019/12/31"[PDat] )”
Filter for
more
screening:
removed 8 studies from failing to meet eligiblity

PubMed Search – Search 2:
Initial
Query:

(mood disorders[mh] OR substance-related disorders[mh])
AND ("vagus nerve stimulation"[tw] OR "invasive brain
stimulation"[mh])

Additional AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR
Filters to
systematic[sb] OR Practice Guideline[ptyp] OR
include:
Guideline[ptyp] OR Evaluation Study[ptyp] OR
Randomized Controlled Trial[ptyp] ) AND "last 5
years"[PDat] AND English[lang]
Modify
Change “AND last 5 years"[PDat with “AND (
"2017/01/01"[PDat] : "2019/12/31"[PDat] )”
Filter for
201 entries -> 39 -> 26 = 1
more
screening:
removed 25 studies from failing to meet eligiblity

10 entries

2 studies
(Aaronson)(Rachid)

# of Included Studies
201 studies

39 studies

26 entries

1 study (McGirr)
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PubMed Search 3:
Initial
Query:

substance-related disorders[mh] OR mood disorders[mh])
AND "neuromodulation"[tw] OR "invasive brain
stimulation"[mh])

Additional AND ( Review[ptyp] OR Meta-Analysis[ptyp] OR
Filters to
systematic[sb] OR Practice Guideline[ptyp] OR
include:
Guideline[ptyp] OR Evaluation Study[ptyp]) AND "last 5
years"[PDat] AND English[lang]
Modify
Change “AND last 5 years"[PDat with “AND (
"2017/01/01"[PDat] : "2019/12/31"[PDat] )”
Filter for
more
screening:
removed 30 studies from failing to meet eligiblity

# of Included Studies
128 studies

49 studies

33 entries

3 studies
(Casmari)(Filkowski)
(McIntyre)

Deviation from scoping protocol:
*added from individual searches using disembogues terms and “similar articles” tabs on above
searches: 3 (Milev, Park, Edwards)
Cochrane System Review:
MeSH Terms: Neuromodulation OR Invasive brain stimulation OR Deep brain stimulation OR
DBS or Vagal nerve stimulation OR VNS
3 systemic reviews were identified, but all 3 were excluded as they did not fit the
inclusion strategy (were for movement conditions)
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